United Therapeutics grants 2,380 options to director
United Therapeutics Corp director Christopher Causey received an annual non-employee director stock option award covering 2,380 shares of common stock at a $527.07 exercise price, expiring July 22, 2033.
Rhea-AI Filing Summary
United Therapeutics Corp director Christopher Causey received an annual non-employee director stock option award covering 2,380 shares of common stock at a $527.07 exercise price, expiring July 22, 2033. The options become fully vested on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following this grant, he directly holds 4,190 common shares and options on 2,380 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 2,380 shares
Grant/Award
2 txns
Insider
CAUSEY CHRISTOPHER
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option F1, F2 | 2,380 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 2,380 contracts (Direct);
Common Stock — 4,190 shares (Direct)
Footnotes (2)
- F1. Annual non-employee director award.
- F2. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
Key Figures
Stock options granted: 2,380 shares
Exercise price: $527.07 per share
Option expiration: July 22, 2033
+3 more
6 metrics
Stock options granted
2,380 shares
Annual non-employee director award on July 22, 2026
Exercise price
$527.07 per share
Conversion or exercise price of granted stock options
Option expiration
July 22, 2033
Expiration date of director stock option award
Common stock holdings
4,190 shares
Direct United Therapeutics common shares held after reported transactions
Underlying common shares
2,380 shares
Shares of common stock underlying the granted stock options
Anticipated vesting date
June 25, 2027
Anticipated date of next Annual Meeting when award may fully vest
Key Terms
Stock Option, Annual non-employee director award, exercise price, expiration date
4 terms
Stock Option financial
"Security title reported as Stock Option for the grant"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Annual non-employee director award financial
"Described in the footnote as an annual non-employee director award"
exercise price financial
"Conversion or exercise price of $527.0700 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"Option award shows an expiration date of 2033-07-22"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did UTHR director Christopher Causey report?
Christopher Causey reported receiving an annual non-employee director stock option award for 2,380 shares on July 22, 2026. The options carry a $527.07 exercise price and expire on July 22, 2033, providing equity-based compensation tied to United Therapeutics’ common stock.
What are the key terms of Christopher Causey’s UTHR stock option grant?
The grant covers 2,380 shares of United Therapeutics common stock at a $527.07 exercise price, expiring July 22, 2033. It is designated as an annual non-employee director award, with vesting linked to either time in service or the next Annual Meeting.
When do Christopher Causey’s UTHR stock options vest?
The options become fully vested on the earlier of the one-year anniversary of the July 22, 2026 grant or the next Annual Meeting of Shareholders. The anticipated vesting date is June 25, 2027, assuming that is when the next Annual Meeting occurs.
Is Christopher Causey’s UTHR option grant part of a routine director compensation program?
Yes. Footnotes describe the grant as an annual non-employee director award with a standard vesting schedule. Vesting occurs by the earlier of one year from grant or the next Annual Meeting, indicating it is part of a recurring board compensation structure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
